K562 AZQR Cell Line

Please Enter Your Email ID
Email ID

Cat. #153252

K562 AZQR Cell Line

Cat. #: 153252

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Organism: Human

Tissue: Lymphatic Tissue

Disease: Cancer

Model: Tumour line


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: Timothy Ward

Institute: Cancer Research UK Manchester Institute

Tool Details

Tool Details


  • Name: K562 AZQR Cell Line
  • Cancer: Blood cancer
  • Cancers detailed: Human caucasian chronic myelogenous leukemia (drug resistant)
  • Research fields: Cancer;Drug development
  • Tool sub type: Continuous
  • Parental cell: K562
  • Organism: Human
  • Tissue: Lymphatic Tissue
  • Disease: Cancer
  • Growth properties: Suspension
  • Model: Tumour line
  • Conditional: No
  • Description: The cells have been shown to contain decreased levels of glutathione and superoxoid dismutase. They are cross-resistant to adriamycin, mitzolamide, MMNG and mitmycin. Cells should be challenged with AZQ at every 4th passage at a minimum density of 100,000 cells/ml. It is recommended to cultivate the cells without drug on resuscitation.
  • Production details: The drug resistant cell line K562 AZQ was developed from the parent K562 cell line by treatment with AZQ C215-bis (carboethoxyamino)-3, 6-diazitinyl 1;4 (benzoquinone).
  • Cellosaurus id: CVCL_2967


  • Format: Frozen
  • Growth medium: Subculture Routine: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37?‚°C.Culture Medium: RPMI 1640 + 10% Foetal Bovine Serum (FBS) + 2mM Glutamine. Challenge with 1 mM AZQ every 4th passage.
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice


  • Ward et al. 1995. Biochem Pharmacol. 50(4):459-64. PMID: 7646550.
  • Cross-resistance studies on two K562 sublines resistant to diaziridinylbenzoquinones.